drugset / Trial / NCT05494190

The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma

NCT05494190

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

Timeline

Start
2022-11-01
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 750 mg/m2 Oral
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Docetaxel Small molecule 60 mg/m2 Intravenous